These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32366717)

  • 1. Distribution of Linezolid in Tuberculosis Lesions in Patients with Spinal Multidrug-Resistant Tuberculosis.
    Li Y; Dong W; Lan T; Fan J; Qin S; Guo A
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis.
    Li Y; Huang H; Dong W; Lan T; Fan J; Wen S; Zhang T; Qin S; Guo A
    PLoS One; 2019; 14(10):e0223391. PubMed ID: 31581274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone penetration of linezolid in osteoarticular tuberculosis patients of China.
    Wen S; Zhang T; Yu X; Dong W; Lan T; Fan J; Xue Y; Wang F; Dong L; Qin S; Huang H
    Int J Infect Dis; 2021 Feb; 103():364-369. PubMed ID: 33278623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential distribution of linezolid in diseased and nondiseased bones in patients with spinal tuberculosis.
    Li Y; Lei G; Dong W; Lan T; Fan J; Qin S
    BMC Infect Dis; 2024 Jan; 24(1):50. PubMed ID: 38182990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of
    Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
    Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
    Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.
    Vu DH; Bolhuis MS; Koster RA; Greijdanus B; de Lange WC; van Altena R; Brouwers JR; Uges DR; Alffenaar JW
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5758-63. PubMed ID: 22926568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased mortality seen in rifampicin/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China.
    Fang MT; Su YF; An HR; Zhang PZ; Deng GF; Liu HM; Mao Z; Zeng JF; Li G; Yang QT; Wang ZY
    BMC Infect Dis; 2021 Sep; 21(1):1015. PubMed ID: 34583653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid in the treatment of multidrug-resistant tuberculosis.
    Schecter GF; Scott C; True L; Raftery A; Flood J; Mase S
    Clin Infect Dis; 2010 Jan; 50(1):49-55. PubMed ID: 19947856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of second-line antituberculosis drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis complex isolates by E-test method].
    Şimşek H; Tarhan G; Cesur S
    Mikrobiyol Bul; 2015 Jan; 49(1):47-55. PubMed ID: 25706730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates.
    Zou L; Liu M; Wang Y; Lu J; Pang Y
    Tuberculosis (Edinb); 2015 Dec; 95(6):839-842. PubMed ID: 26395151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China.
    Zhang Z; Pang Y; Wang Y; Liu C; Zhao Y
    Int J Antimicrob Agents; 2014 Mar; 43(3):231-5. PubMed ID: 24439458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid in the treatment of MDR-TB: a retrospective clinical study.
    Xu HB; Jiang RH; Li L; Xiao HP
    Int J Tuberc Lung Dis; 2012; 16(3):358-63. PubMed ID: 22640450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis.
    Wasserman S; Huo S; Ky K; Malig YN; Esmail A; Dheda K; Bacchetti P; Gerona R; Maartens G; Gandhi M; Metcalfe J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31932382
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey.
    Wang G; Jiang G; Jing W; Zong Z; Yu X; Chen S; Li W; Huang H
    J Infect; 2021 Mar; 82(3):371-377. PubMed ID: 33556430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Evaluation of Linezolid and Meropenem Against Clinical Isolates of Multi Drug Resistant Tuberculosis By Mycobacterial Growth Indicator Tube (MGIT) 960.
    Mirza IA; Satti L; Khan FA; Khan KA
    J Coll Physicians Surg Pak; 2015 Jun; 25(6):427-30. PubMed ID: 26100995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.